Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pyxis Oncology (PYXS) Change in Accured Expenses (2024 - 2025)

Pyxis Oncology (PYXS) has disclosed Change in Accured Expenses for 2 consecutive years, with $1.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Change in Accured Expenses fell 67.29% to $1.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$6.1 million, a N/A change, with the full-year FY2024 number at -$1.7 million, up 88.15% from a year prior.
  • Change in Accured Expenses was $1.3 million for Q3 2025 at Pyxis Oncology, up from -$3.4 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $4.0 million in Q3 2024 to a low of -$3.4 million in Q2 2025.